TippingPoint Biosciences builds a novel drug discovery platform that recreates disease-specific chromatin environments to expose transient protein–protein interfaces within the epigenome that are otherwise inaccessible. The company aims to discover first-in-class, highly selective drugs that target these epigenetic interfaces while sparing healthy cells. TippingPoint’s initial therapeutic focus is on Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive pediatric brainstem tumor driven by chromatin dysfunction. The company was co-founded by Laura Hsieh and chromatin biologist Geeta Narlikar and was spun out of Narlikar’s lab at UCSF. TippingPoint has raised $2.5 million in pre-seed financing including non-dilutive grants and foundation support, received several Golden Ticket awards, and has now closed a $4.5 million seed round to advance its lead program and expand its discovery platform. The platform is described as applicable to multiple disease areas including cancer, neurodegenerative diseases and developmental disorders.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

Mar 2026